Clinical

Dr Podesta calls on her experience using PDTs with patients to describe what successes and challenges are common.

A new report offers novel insights into a very small patient population.

Researchers emphasize the importance of characterizing and recognizing this subtype to identify patients at risk of Kaposi sarcoma.

About 43% of patients experienced complete depletion of B cells after the first round of rituximab, and those patients had greater odds of longer-term success.

A patient’s quick response to cemiplimab (Libtayo) was reversed after the therapy was stopped due to progression of apparent metastatic cutaneous squamous cell carcinoma.

A recent review summarized the current knowledge and treatment paradigm of multiple myeloma, including recent advances and challenges in nanomedicine. 

A dichotomous classification scheme has helped in the intrahepatic cholangiocarcinoma (iCCA) space, but some potential variants require further exploration, the article states.

Transfusion dependence is common for patients with myelodysplastic syndromes (MDS), but real-world data show inconsistent patient experiences and varied transfusion practices between countries.

Surveys of health care professionals, patients, and caregivers explored unmet needs in sickle cell disease (SCD), as well as the significant impact the disease has on everyday life.

Major adverse cardiac events are rare but serious in patients treated with immune checkpoint inhibitors (ICIs), and increased awareness is crucial to identify and treat these conditions in a timely manner.

High-intensity interval training (HIIT) also improved quality of life and physical activity levels while reducing anxiety and depression levels.

Levels of the hormone increase with disease severity, a new study has found.

Omid A. Hamid, MD, chief of Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, spoke with The American Journal of Managed Care® (AJMC®) about evaluating therapy options for patients with advanced melanoma.

A literature review revealed that supplementation with vitamin D could provide therapeutic benefits for patients with multiple myeloma (MM) who are undergoing chemotherapy. However, more research is needed to confirm findings.

Immune checkpoint inhibitors have changed the way certain cancers are treated, but more can be done to optimize treatment and improve patient responses.

Investigators said the benefits appeared relatively early in treatment for many patients and persisted throughout the study period.

A single-center analysis of more than 30 years of data shows rates of preterm births and preeclampsia remained stable

A recent study found that the Service Apothecary Respiratory Advice eHealth intervention could help patients with chronic obstructive pulmonary disease with exacerbation rates and medication adherence.

Prior miscarriage and antinuclear antibody positivity are independent risk factors associated with adverse pregnancy outcomes among women with rheumatoid arthritis (RA).

Drs Noble and Highland explain the typical treatment goals physicians aim for when looking at ILD therapy options.

Ryan Haumschild, PharmD, MS, MBA, and Kristin Highland, MD, explain the clinical and economic burdens associated with ILD treatment.

Two experts highlight their preferred treatment options for RRMM based on each line of therapy the patient will need.

Drs Kaufman and Richter outline important considerations physicians should be aware of when selecting IMiD therapy for a patient with RRMM.

The FDA is faster to approve new oncology therapies compared with the European Medicines Agency (EMA); but that speed may have consequences.

Arwen Podesta, MD, provides an overview of how PDTs have evolved over the past 6 years since their introduction into the medical world.

Two experts define prescription digital therapeutics (PDTs) and their role in behavioral care therapy.

Oxidative stress, including DNA damage and malondialdehyde, was associated with dementia in patients with chronic obstructive pulmonary disease (COPD).

While no agents are approved just yet, a variety of promising drugs targeting CLDN18.2 are undergoing early research and clinical trials for several cancer types. 

Elli Papaemmanuil, PhD, assistant professor in computational oncology, Memorial Sloan Kettering Cancer Center, spoke on current methods of classification and stratification for myelodysplastic syndromes (MDS) and the applicability of a novel scoring system, presented during her plenary session at EHA2022, that aims to improve and refine MDS risk estimation.

John Mascarenhas, MD, director of the Adult Leukemia Program at The Tisch Cancer Institute at Mount Sinai, spoke on preliminary data findings of the phase 2 MANIFEST study investigating the efficacy and safety profile of pelabresib, ruxolitinib combination therapy in JAK inhibitor-naive patients with myelofibrosis and those with suboptimal response to ruxolitinib monotherapy.